Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FENC
HOLDFennec Pharmaceuticals Inc. · Healthcare · United States · $347M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Fennec Pharmaceuticals is a specialty pharmaceutical company focused on oncology supportive care. Its lead product, PEDMARK (sodium thiosulfate), is the first and only FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin chemotherapy in pediatric patients with localized, non-metastatic solid tumors. The company occupies a critical niche addressing an unmet medical need in pediatric cancer care.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5M | 21.3M | 47.5M | 44.6M | 207.5% | 51.0M | 69.8M | 100.4M | 50.0% |
| EPS | -0.90 | -0.60 | 0.00 | -0.35 | — | -0.27 | — | — | — |
| Shares | 26.4M | 27.0M | 27.5M | 34.2M | +29.6% | 34.7M | — | — | — |
| Debt | 24.9M | 31.0M | 19.3M | 0 | -11.9% | — | — | — | — |
| Equity | -2.6M | -11.6M | -5.9M | 35.5M | — | — | — | — | — |
| Op CF | -18.1M | -17.1M | 27.0M | -12.5M | — | -5.8M | — | — | — |
| Inv CF | — | — | — | — | — | — | — | — | — |
| Fin CF | 20.7M | 6.6M | -13.6M | 22.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FENC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FENC | Fennec Pharmaceuticals Inc.(you) | $347M | 53 | HOLD |
| ABEO | Abeona Therapeutics Inc. | $345M | 58 | HOLD |
| RLMD | Relmada Therapeutics, Inc. | $544M | 51 | HOLD |
| IKT | Inhibikase Therapeutics, Inc. | $366M | 41 | HOLD |
| AGEN | Agenus Inc. | $249M | 61 | HOLD |
| ORMP | Oramed Pharmaceuticals Inc. | $165M | 58 | HOLD |
| TBPH | Theravance Biopharma, Inc. | $874M | 54 | HOLD |
| FTH | Faeth Therapeutics, Inc. | $729M | 47 | HOLD |
| XFOR | X4 Pharmaceuticals, Inc. | $363M | 32 | SELL |
| CCCC | C4 Therapeutics, Inc. | $376M | 33 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%